What is Tornalate used for?

Tornalate is indicated for Acute exacerbation of asthma, Asthma, Asthma management, Bronchiectasis, Bronchitis.

Tornalate is developed by Sanofi.

What development phase is Tornalate in?

Tornalate is FDA-approved (marketed).

What is the generic name of Tornalate?

BITOLTEROL is the generic (nonproprietary) name of Tornalate.

Last reviewed 2026-04-20 · How we verify

Tornalate (BITOLTEROL)

Sanofi · FDA-approved approved Small molecule Quality 24/100

Tornalate (bitolterol) is a small molecule drug developed by Sanofi Aventis US that targets the beta-2 adrenergic receptor. It was approved by the FDA in 1984 for various respiratory indications, including asthma, bronchitis, and pulmonary emphysema. Despite being off-patent, there are currently no generic manufacturers of the drug. Tornalate is used to prevent bronchospasm and manage symptoms of respiratory diseases. Its commercial status and pharmacokinetic properties are not well-documented.

At a glance

Generic name	BITOLTEROL
Sponsor	Sanofi
Drug class	bitolterol
Target	Beta-2 adrenergic receptor
Modality	Small molecule
Therapeutic area	Respiratory
Phase	FDA-approved
First approval	1984

Approved indications

Acute exacerbation of asthma
Asthma
Asthma management
Bronchiectasis
Bronchitis
Bronchospasm Prevention
Pulmonary emphysema

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Tornalate CI brief — competitive landscape report
Tornalate updates RSS · CI watch RSS
Sanofi portfolio CI